Pharm D Year 4, 4.5 Biopharmaceutics and Pharmacokinetics — Pharm D Year 4

Unit 1: Introduction to Biopharmaceutics

Syllabus scope

Biopharmaceutics examines how formulation and physicochemical properties influence the rate and extent of drug entry into the systemic circulation. This unit introduces the connection between dosage form, absorption, distribution, and elimination.

Rate and extent

The rate of absorption affects time to peak concentration and onset. The extent affects systemic exposure. A drug can have a rapid rate but low extent, or a slow rate with similar total exposure. The formulation, route, dose, solubility, permeability, gastrointestinal movement, food, disease, and interactions all matter.

Biopharmaceutic pathway

1. The dosage form releases drug.
2. The drug dissolves in biological fluid.
3. It crosses an absorption barrier.
4. It enters blood and may undergo first-pass loss.
5. It distributes between compartments.
6. It is metabolized or excreted.
7. Concentration and response are monitored.

The Biopharmaceutics Classification System relates solubility and permeability, but classification does not remove the need to evaluate formulation, dose, excipients, and regulatory criteria.

Clinical correlation

A formulation switch can alter exposure even when the labelled dose is unchanged. The pharmacist should ask about brand or formulation changes, administration with food, crushing or splitting, and release characteristics.

Worked example

If a tablet dissolves slowly, absorption may be dissolution limited. Improving particle size or formulation wetting may increase release, but the final effect must be demonstrated through appropriate dissolution and bioavailability evidence.

FAQs

Does higher plasma concentration always mean better therapy? No. Exposure must be related to efficacy, toxicity, and the therapeutic window.

Why distinguish rate and extent? They affect onset, peak effects, total exposure, and interchangeability.

Takeaways

• Drug release, dissolution, permeability, and first pass shape exposure.
• Formulation changes can alter clinical performance.
• Connect in vitro behavior with in vivo evidence carefully.

Integrated practice note

Biopharmaceutics is a bridge between formulation and patient care. A change in excipient, manufacturing process, release profile, or administration instruction may alter exposure. The pharmacist should ask what changed, how the change was tested, and whether the product remains appropriate for the patient. If evidence is incomplete, the uncertainty should be documented rather than hidden behind the same labelled dose. The same reasoning applies to substitutions, feeding-tube administration, modified-release products, and medicines with narrow therapeutic windows. The patient’s actual use is part of the exposure system.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Shargel and Yu, Applied Biopharmaceutics and Pharmacokinetics, latest available edition.

Unit 2: Gastrointestinal Absorption

Syllabus scope

This unit covers drug absorption from the gastrointestinal tract.

Absorption mechanisms

Most drugs cross biological membranes by passive diffusion, driven by a concentration gradient and influenced by lipophilicity, ionization, surface area, and membrane thickness. Some substances use carrier-mediated transport, which may be saturable or subject to competition. Endocytosis and paracellular movement are relevant for selected molecules.

Absorption sequence

1. The dosage form disintegrates and releases drug.
2. Drug dissolves in gastrointestinal fluid.
3. The unionized fraction partitions into the membrane.
4. The molecule crosses enterocytes or paracellular pathways.
5. Efflux transporters or metabolism may reduce entry.
6. Portal blood carries absorbed drug to the liver.
7. First-pass metabolism reduces the fraction reaching systemic blood.

The pH partition concept predicts that weak acids are more unionized in acidic environments and weak bases in less acidic environments, but real absorption also depends on surface area, transit, solubility, formulation, transporters, and metabolism.

Factors affecting absorption

Food can delay gastric emptying, alter bile secretion, bind drug, change pH, or improve solubilization. Disease, surgery, diarrhoea, constipation, inflammation, age, excipients, and drug interactions also matter. Extended-release products should not be crushed unless the formulation is designed for it.

Clinical correlation

A patient who takes a medicine with an interacting mineral supplement may reduce absorption through complexation. A pharmacist should check timing and product instructions rather than assume that every interaction is solved by separating doses.

Worked example

For a weakly basic drug with poor solubility at higher intestinal pH, gastric pH modifiers may reduce dissolution and exposure. The pharmacist reviews timing, formulation, clinical response, and the evidence for the specific medicine.

FAQs

Does a larger dose always produce proportionally larger exposure? Only when absorption and elimination remain linear and unsaturated.

Why does first-pass metabolism matter? It reduces systemic availability after oral administration.

Takeaways

• Dissolution precedes membrane crossing.
• pH, food, transit, transporters, and metabolism can change absorption.
• Administration instructions are part of dosage-form performance.

Integrated practice note

Absorption problems may be formulation related, patient related, or interaction related. Review the product, preparation, timing, food, supplements, gastric conditions, intestinal disease, and adherence together. A low concentration should not be interpreted as malabsorption until sampling time, dose history, assay, and alternative explanations have been checked.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Rowland and Tozer, Clinical Pharmacokinetics and Pharmacodynamics, latest available edition.

Unit 3: Drug Distribution and Elimination

Syllabus scope

This unit covers drug distribution and elimination.

Distribution

After entering blood, drug distributes between plasma and tissues. Distribution depends on blood flow, permeability, lipid solubility, tissue binding, plasma-protein binding, body composition, and disease. A volume of distribution is an apparent volume relating amount in the body to measured plasma concentration. It is not necessarily an anatomical space.

Distribution mechanism

1. Drug reaches an organ through blood flow.
2. It crosses or is retained by barriers.
3. It binds plasma proteins or tissue components.
4. Free drug equilibrates between compartments.
5. Changes in protein binding or tissue perfusion alter free concentration.

Only free drug generally crosses membranes, is available for receptor interaction, and is cleared. A sudden change in binding can alter free exposure even when total concentration appears unchanged.

Elimination

Elimination combines metabolism and excretion. Hepatic metabolism may involve oxidation, reduction, hydrolysis, conjugation, transport, and active metabolites. Renal elimination involves filtration, secretion, and reabsorption. Biliary and pulmonary routes may also contribute.

Clearance describes the hypothetical plasma volume cleared of drug per unit time. Half-life depends on clearance and volume of distribution. Changing either can change duration and accumulation.

Clinical correlation

Hypoalbuminaemia, renal failure, liver disease, oedema, obesity, pregnancy, burns, and critical illness can alter distribution and clearance. The pharmacist should use the patient-specific dosing method and not substitute a remembered number.

Worked example

A highly protein-bound medicine is given to a patient with low albumin. The total concentration may not reflect free exposure. The pharmacist reviews clinical response, toxicity, albumin, interacting medicines, and whether free concentration measurement is meaningful.

FAQs

Is volume of distribution a real body volume? It is an apparent pharmacokinetic parameter.

Why does renal function affect some medicines more than others? Dependence on renal clearance differs between drugs and metabolites.

Takeaways

• Distribution depends on free drug, barriers, blood flow, and binding.
• Clearance and volume jointly influence half-life.
• Organ impairment requires patient-specific assessment.

Integrated practice note

Distribution and elimination parameters are tools for a dosing decision, not isolated facts. Consider whether the medicine has a narrow therapeutic window, whether the measured concentration is total or free, whether the patient is at steady state, and whether organ function is changing. Reassess after surgery, fluid shifts, critical illness, or major nutritional change. A parameter estimated in healthy volunteers may not transfer directly to a critically ill patient. The pharmacist should identify the population, model, assay, and clinical setting before applying it.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, latest available edition.

Unit 4: Pharmacokinetic Models and Drug Concentrations

Syllabus scope

This unit covers mathematical models, drug levels in blood, compartment models, and pharmacokinetic studies.

Models

A pharmacokinetic model simplifies the body to describe concentration over time. A one-compartment model assumes rapid distribution into one kinetically uniform space. A multicompartment model separates an initial distribution phase from a slower terminal phase. These are mathematical descriptions, not literal anatomy.

Study sequence

1. Select dose, route, sampling schedule, and assay.
2. Collect timed samples with accurate documentation.
3. Measure concentration and verify data quality.
4. Plot concentration against time.
5. Fit an appropriate model or use noncompartmental analysis.
6. Estimate parameters and uncertainty.
7. Relate parameters to dosing and safety.

For first-order elimination, a constant fraction is removed per unit time, producing an exponential decline. On a semilogarithmic plot, a first-order single-compartment decline can approximate a straight line. Zero-order elimination removes a constant amount per time and may arise when a pathway is saturated.

Pharmacokinetic studies

Study design depends on route, formulation, sampling duration, assay sensitivity, expected half-life, and the question being asked. Sampling too early may miss the peak; stopping too soon may miss the terminal phase.

Clinical correlation

A misleading model can produce unsafe dose recommendations. Always check whether the sampling interval, assay, patient state, and residual pattern support the model.

Worked example

If concentrations fall rapidly at first and slowly later, a two-compartment model may describe the curve better than a single straight line. The pharmacist should not interpret the early slope as the elimination rate without considering distribution.

FAQs

Are compartments anatomical organs? Usually no. They are kinetic spaces.

Why use a semilog plot? It can make exponential decline easier to identify and estimate.

Takeaways

• Match model complexity to data and purpose.
• Sampling design determines what can be estimated.
• Inspect plots and assumptions before trusting parameters.

Integrated practice note

Model fitting should be judged by clinical usefulness as well as statistical fit. Examine residuals, sampling gaps, parameter plausibility, and sensitivity to early or late observations. A complicated model is not automatically better. The chosen model should answer the stated question and make its uncertainty visible to the clinician using the result.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Gibaldi and Perrier, Pharmacokinetics, latest available edition.

Unit 5: One-Compartment Open Model

Syllabus scope

This unit covers intravenous bolus injection and intravenous infusion using a one-compartment open model.

Intravenous bolus

After an intravenous bolus in a one-compartment model, the drug is considered instantaneously mixed. Concentration declines by elimination. The model uses dose, concentration, volume of distribution, clearance, elimination rate constant, and half-life.

Bolus reasoning

1. Dose enters systemic circulation immediately.
2. Initial concentration relates dose to apparent volume.
3. Elimination removes a fraction over time.
4. Concentration follows an exponential decline under first-order conditions.
5. Half-life describes the time for concentration to fall by half.

The area under the concentration-time curve represents systemic exposure. Clearance relates dose to exposure. A larger volume lowers initial concentration for the same dose; lower clearance prolongs exposure.

Intravenous infusion

During constant-rate infusion, input continues while elimination rises with concentration. Concentration approaches a steady state when input equals elimination. The time to approach steady state depends mainly on the elimination half-life, not the infusion rate. A loading dose can reach a target faster, but it must be calculated safely.

Worked example

If a continuous infusion is stopped before steady state, the concentration may be lower than the eventual target. The pharmacist should consider infusion duration, half-life, line issues, sampling time, and whether a loading strategy is appropriate rather than escalating the rate solely from an early sample.

Clinical correlation

Rapid bolus administration may cause high peak-related toxicity even when total exposure is acceptable. Infusion rate, access, compatibility, monitoring, and patient response matter.

FAQs

What determines steady state? Continued input, elimination, and sufficient time relative to half-life.

Why can a loading dose be risky? It produces a rapid concentration increase and may be unsafe when the target or volume estimate is uncertain.

Takeaways

• Bolus dosing and infusion create different concentration profiles.
• Clearance controls maintenance input at steady state.
• Peak, exposure, and administration rate all matter.

Integrated practice note

For an intravenous regimen, document dose, concentration, infusion or injection time, line access, sampling time, and patient response. A concentration obtained during an infusion or immediately after a bolus may not represent the intended monitoring point. Before changing therapy, verify the sampling event and the model used to interpret it.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Rowland and Tozer, Clinical Pharmacokinetics and Pharmacodynamics, latest available edition.

Unit 6: Two-Compartment Open Models

Syllabus scope

This unit covers intravenous bolus, intravenous infusion, and oral administration using a two-compartment open model.

Model

The central compartment represents rapidly equilibrating blood and highly perfused tissues. The peripheral compartment represents slower distribution. After a bolus, concentration often shows a rapid distribution phase followed by a terminal phase. Microconstants describe movement between compartments, while hybrid constants describe the observed curve.

Model reasoning

1. Drug enters the central compartment.
2. It distributes to the peripheral compartment.
3. Elimination occurs from the central compartment or through defined pathways.
4. Distribution and elimination produce a biexponential concentration curve.
5. Infusion or oral input changes the curve according to its rate and absorption.

Oral administration

Oral dosing adds an absorption process. If absorption is slower than terminal disposition, a flip-flop pattern can occur, in which the apparent terminal slope reflects absorption rather than elimination. Sampling design and prior knowledge are essential.

Clinical correlation

A two-compartment model can matter when early concentration drives toxicity or when tissue distribution affects duration. It is especially relevant when a simple one-compartment assumption produces systematic residual error.

Worked example

Two patients have the same terminal half-life but different early concentrations after a bolus. The pharmacist should not assume identical peak risk. Distribution volume, infusion rate, body composition, and central clearance may differ.

FAQs

Does a peripheral compartment mean a specific organ? No. It is a kinetic representation.

What is flip-flop? The terminal observed decline is governed by absorption when absorption is slower than disposition.

Takeaways

• Multicompartment curves separate distribution and terminal behavior.
• Oral, bolus, and infusion inputs produce different profiles.
• Model choice must follow data and the clinical question.

Integrated practice note

Multicompartment behavior is especially important when early toxicity and late persistence have different causes. A patient may have a high initial concentration because of distribution characteristics while a later sample reflects elimination. Clinical interpretation should therefore include the time course, not only one calculated half-life or one concentration.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Gibaldi and Perrier, Pharmacokinetics, latest available edition.

Unit 7: Multiple-Dose Regimens

Syllabus scope

This unit covers repeated intravenous injections, repeated extravascular dosing in a one-compartment open model, and multiple dosing in a two-compartment open model.

Accumulation

With repeated dosing, residual drug from earlier doses adds to new input. Concentration rises until the average input equals average elimination. Accumulation depends on dosing interval relative to half-life. Shorter intervals may reduce fluctuation but increase the risk of accumulation if the dose is not adjusted.

Regimen reasoning

1. Define target exposure and acceptable peak-trough fluctuation.
2. Estimate clearance, volume, half-life, and bioavailability.
3. Select dose and interval.
4. Predict accumulation and time to steady state.
5. Monitor response, toxicity, adherence, and sampling time.
6. Adjust one or more regimen components using patient data.

Repeated extravascular dosing adds absorption and possible first-pass loss. A missed dose can alter exposure differently for immediate and extended-release products. Two-compartment accumulation can involve distribution disequilibrium, so early and late concentrations require different interpretation.

Worked example

If the dosing interval is lengthened without changing dose, average exposure may fall while fluctuation increases. If the dose is doubled without changing interval, average exposure and peak risk may rise. The correct change depends on therapeutic goal, clearance, and patient response.

Clinical correlation

Therapeutic drug monitoring is useful only when the sample is linked to dose history and the pharmacokinetic model. A concentration without dose time, administration time, and sampling time can mislead.

FAQs

Does steady state mean the concentration is constant? No. It means the repeating profile is stable from interval to interval.

Why is sample timing essential? Peaks, troughs, and random concentrations answer different questions.

Takeaways

• Accumulation depends on interval and half-life.
• Regimen adjustment must consider exposure and fluctuation.
• Document dose and sample times for interpretation.

Integrated practice note

Steady-state monitoring should occur after enough time for the regimen to approach its repeating profile unless an earlier measurement has a specific purpose. When adherence is uncertain, a concentration may reflect missed or delayed doses rather than pharmacokinetics. Ask about actual administration and record the timing before adjusting a dose.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Rowland and Tozer, Clinical Pharmacokinetics and Pharmacodynamics, latest available edition.

Unit 8: Nonlinear Pharmacokinetics

Syllabus scope

This unit covers nonlinearity, causes of nonlinearity, and Michaelis-Menten estimation of parameters.

Nonlinearity

Pharmacokinetics is nonlinear when dose or concentration changes alter exposure disproportionately. Causes include saturation of metabolism, transport, protein binding, renal secretion, or absorption; autoinduction or inhibition; capacity-limited dissolution; and dose-dependent bioavailability.

Nonlinear reasoning

1. Compare dose, concentration, clearance, and exposure across levels.
2. Look for disproportional changes in area under the curve or half-life.
3. Identify a saturable step.
4. Determine whether the process is input, distribution, metabolism, or excretion.
5. Use a model appropriate to the mechanism.
6. Monitor closely when dose changes.

Michaelis-Menten elimination can be represented by a maximum elimination rate and a concentration at half that rate. At low concentration, elimination may approximate first-order behavior. Near saturation, small dose increases can cause large concentration increases.

Clinical correlation

Nonlinearity increases toxicity risk because dose proportionality cannot be assumed. Interactions may be more serious near saturation, and dose changes require clinical and laboratory monitoring.

Worked example

If doubling the dose more than doubles exposure, a saturable elimination pathway is possible. The pharmacist checks adherence, assay, dose history, disease changes, and other causes before concluding nonlinearity.

FAQs

Can half-life remain constant in nonlinear kinetics? Not necessarily. It may change with concentration.

Why is a straight-line clearance assumption risky? It can underestimate exposure after dose escalation.

Takeaways

• Test dose proportionality rather than assuming it.
• Identify the saturable step.
• Use cautious titration and monitoring near capacity limits.

Integrated practice note

Nonlinearity should be suspected when exposure, clearance, or half-life changes disproportionately with dose. Confirm the pattern with reliable dose and concentration records, then consider saturation, inhibition, induction, organ change, and assay problems. Titrate cautiously and define monitoring before increasing the dose.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Gibaldi and Perrier, Pharmacokinetics, latest available edition.

Unit 9: Noncompartmental Pharmacokinetics

Syllabus scope

This unit covers statistical moment theory, mean residence time for compartment models, and physiological pharmacokinetic models.

Statistical moments

Noncompartmental analysis uses concentration-time data without imposing a specific compartment structure. The area under the curve estimates exposure. The area under the first moment curve weights concentration by time. Mean residence time is the ratio of the first moment area to the area under the curve under appropriate assumptions.

Analysis sequence

1. Confirm dose, route, sampling times, and assay quality.
2. Calculate or estimate the concentration-time area.
3. Estimate the first moment area.
4. Derive mean residence time and related parameters.
5. Check terminal sampling and extrapolation.
6. Interpret with route, dose, and bioavailability in mind.

Physiological pharmacokinetic models represent organs or tissues using blood flow, partitioning, binding, and organ-specific clearance. They may support extrapolation and mechanistic interpretation but require reliable physiological and drug-specific parameters.

Clinical correlation

Noncompartmental parameters are useful for exposure comparison but do not automatically explain the mechanism of distribution. The pharmacist should not use a parameter outside the assumptions under which it was estimated.

Worked example

Two formulations have similar area under the curve but different time to peak. They may have similar extent of exposure with different absorption rate. The clinical effect depends on therapeutic window and whether peak or onset matters.

FAQs

Does noncompartmental analysis assume no model? It avoids a specific compartment structure but still uses assumptions about sampling, terminal behavior, and input.

What does mean residence time describe? An average time drug molecules remain in the system under the analysis conditions.

Takeaways

• Use moments to summarize exposure and residence.
• Inspect terminal extrapolation and sampling adequacy.
• Physiological models require credible parameters.

Integrated practice note

Noncompartmental results are sensitive to the quality and duration of sampling. If the terminal phase is poorly captured, extrapolated exposure may be unreliable. State the percentage extrapolated, the route and dose, the sampling schedule, and the assumptions used. Compare formulations under matching conditions and interpret a parameter only within its validated context.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Rowland and Tozer, Clinical Pharmacokinetics and Pharmacodynamics, latest available edition.

Unit 10: Bioavailability and Bioequivalence

Syllabus scope

This unit covers bioavailability, study protocols, and methods of assessing bioavailability and bioequivalence.

Bioavailability

Bioavailability is the rate and extent to which an active ingredient becomes available at the site of action or systemic circulation, depending on the definition used. Intravenous administration is generally the reference for absolute bioavailability. Relative bioavailability compares formulations or routes.

Study mechanism

1. Define the formulation, dose, route, population, and comparison.
2. Standardize meals, posture, fluid, timing, and restrictions as required.
3. Collect samples long enough to characterize absorption and elimination.
4. Measure concentrations with a validated assay.
5. Estimate area under the curve and peak-related parameters.
6. Analyze within-subject variability and confidence intervals according to the approved method.

Area under the curve mainly reflects extent of exposure, while peak concentration and time to peak reflect rate and timing. Urinary excretion data may support assessment when renal excretion of unchanged drug is suitable, but urine collection quality is critical.

Bioequivalence

Bioequivalence asks whether two pharmaceutical products show sufficiently similar bioavailability under defined conditions. The conclusion depends on product, study design, statistical method, acceptance criteria, variability, and regulatory guidance. Current limits and protocol requirements must be checked in the applicable jurisdiction-specific guidance before a conclusion is used.

Clinical correlation

A formulation with similar average exposure may still differ in excipient tolerance, administration instructions, device use, or peak-related effects. The pharmacist should communicate substitution decisions clearly and monitor the patient when clinically relevant.

Worked example

If a test product has a lower area under the curve than the reference, it may have lower extent of absorption, but assay, dosing, adherence, sampling, and variability must be checked before interpretation. A visual difference alone is not a bioequivalence conclusion.

FAQs

Is bioequivalence the same as identical products? No. It addresses defined exposure criteria, not every physical or clinical attribute.

Why standardize meals? Food can alter dissolution, transit, absorption, and metabolism.

Takeaways

• Distinguish rate from extent of availability.
• Use validated protocols and assays.
• Interpret bioequivalence through the applicable regulatory method.

Integrated practice note

Bioavailability studies require careful control of formulation identity, dose, food, posture, fluid, sampling, assay, and analysis. A conclusion should state the population, design, comparison, parameters, confidence interval, and applicable criteria. If the product is intended for a special population or route, the study conditions should be relevant to that use. Regulatory rules can change, so the current applicable guidance must be checked when a jurisdiction or product pathway is specified. Patients should be told when a substitution is made and what to monitor. Documentation should connect the product, dose, route, clinical reason, and follow-up plan.

References

1. PharmacoLearn, Pharm D Year 4 syllabus: https://pharmacolearn.fyi/syllabus/pharm-d/year-4/
2. Pharmacy Council of India, Pharm.D. Regulations, 2008.
3. Shargel and Yu, Applied Biopharmaceutics and Pharmacokinetics, latest available edition.
4. Current national bioequivalence guidance. Confirm exact requirements in the applicable current authority guidance before study design or submission.